Telomir shareholders back all 2026 meeting items

Telomir Pharmaceuticals’ 2026 annual meeting achieved a 68.53% quorum, electing all director nominees and ratifying its 2026 independent auditor.

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. (TELO) reported the results of its 2026 Annual Meeting of Stockholders held on September 11, 2026. Stockholders owning 47,129,480 shares, or 68.53% of the 68,774,954 shares outstanding as of the July 21, 2026 record date, were represented, constituting a quorum.

All three proposals were approved, including the election of directors Erez Aminov, Matthew Whalen, Edward MacPherson and Matthew Del Giudice, M.D. For example, Aminov received 43,363,662 votes for and 93,927 withheld, with 3,671,891 broker non-votes. Stockholders also ratified Salberg & Company, P.A. as independent registered public accounting firm for 2026 with 46,998,583 votes for, and approved a possible adjournment of the meeting with 44,841,042 votes for.

8-K Event Classification

2 items: 5.07, 9.01

2 items

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Shares outstanding on record date: 68,774,954 shares Shares represented at meeting: 47,129,480 shares Quorum percentage: 68.53% +4 more

7 metrics

Shares outstanding on record date 68,774,954 shares Common stock outstanding as of July 21, 2026 record date

Shares represented at meeting 47,129,480 shares Common stock represented and voted by proxy at 2026 Annual Meeting

Quorum percentage 68.53% Percentage of outstanding shares represented at 2026 Annual Meeting

Votes for auditor ratification 46,998,583 votes Votes for ratifying Salberg & Company, P.A. for fiscal year 2026

Votes for adjournment proposal 44,841,042 votes Votes for approving potential adjournment to solicit additional proxies

Votes for director Erez Aminov 43,363,662 votes Votes for electing Erez Aminov as director at 2026 Annual Meeting

Broker non-votes on director elections 3,671,891 votes Broker non-votes reported for each director nominee

Key Terms

broker non-votes, quorum, Record Date, independent registered public accounting firm, +1 more

5 terms

broker non-votes financial

"Nominee | | Votes For | | Votes Withheld | | Broker Non-votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

quorum financial

"constituting a quorum for the Annual Meeting"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

Record Date financial

"The record date for stockholders entitled to notice of and to vote"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

independent registered public accounting firm financial

"appointment of Salberg & Company, P.A. as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was the shareholder quorum at Telomir Pharmaceuticals (TELO)'s 2026 Annual Meeting?

The quorum consisted of 47,129,480 shares of common stock represented by proxy, which equaled 68.53% of the 68,774,954 shares outstanding as of the July 21, 2026 record date.

Which directors were elected at Telomir Pharmaceuticals (TELO)'s 2026 Annual Meeting and how many votes did they receive?

Stockholders elected Erez Aminov, Matthew Whalen, Edward MacPherson, and Matthew Del Giudice, M.D.. For example, Aminov received 43,363,662 votes for, 93,927 withheld, and 3,671,891 broker non-votes.

How many Telomir Pharmaceuticals (TELO) shares were outstanding on the 2026 Annual Meeting record date?

On the July 21, 2026 record date, there were 68,774,954 shares of Telomir Pharmaceuticals common stock outstanding, with each share entitled to one vote at the 2026 Annual Meeting.

Did Telomir Pharmaceuticals (TELO) stockholders ratify the 2026 independent auditor?

Yes. Stockholders ratified the appointment of Salberg & Company, P.A. as the independent registered public accounting firm for the year ending December 31, 2026, with 46,998,583 votes for, 69,548 against, and 61,349 abstentions.

What were the voting results on the adjournment proposal at Telomir Pharmaceuticals (TELO)'s 2026 Annual Meeting?

The adjournment proposal, allowing adjournment if needed to solicit additional proxies for Proposals 1 and 2, was approved with 44,841,042 votes for, 2,271,263 against, and 17,175 abstentions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:31 PM Accepted by SEC EDGAR 09/16/2026 - 04:30 PM Learn about SEC filing dates

false 0001971532 0001971532 2026-09-11 2026-09-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2026

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41952		87-2606031
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matter to a Vote of Security Holders.

On September 11, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The record date for stockholders entitled to notice of and to vote at the Annual Meeting was July 21, 2026 (the “Record Date”). As of the Record Date, there were 68,774,954 shares of the Company’s common stock, no par value per share (the “Common Stock”), outstanding. Each share of Common Stock represents one vote that could be voted on each matter that came before the Annual Meeting.

At the Annual Meeting, 47,129,480 shares of Common Stock were represented and voted by proxy, constituting a quorum for the Annual Meeting. The shares represented approximately 68.53% of the outstanding shares entitled to vote at the Annual Meeting.

At the Annual Meeting, three proposals were submitted to the Company’s stockholders. The proposals are described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on July 28, 2026. Each proposal was approved by the Company’s stockholders.

The final voting results were as follows:

Proposal 1

The Company’s stockholders elected Erez Aminov, Matthew Whalen, Edward MacPherson and Matthew Del Giudice, M.D., as directors of the Company to serve until the next Annual Meeting of Stockholders, or until their respective successors have been duly elected and qualified, based upon the voting results set forth below.

Nominee		Votes For		Votes Withheld		Broker Non-votes
Erez Aminov		43,363,662		93,927		3,671,891
Matthew Pratt Whalen		43,365,060		92,529		3,671,891
Edward MacPherson		41,779,035		1,678,554		3,671,891
Matthew Del Giudice, M.D.		41,238,011		2,219,578		3,671,891

Proposal 2

The Company’s stockholders approved the ratification of the appointment of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, based upon the voting results set forth below.

Votes For		Votes Against		Votes Abstained		Broker Non-votes
46,998,583		69,548		61,349		-

Proposal 3

The Company’s stockholders approved the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 1 and 2.

Votes For		Votes Against		Votes Abstained		Broker Non-votes
44,841,042		2,271,263		17,175		-

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.
Dated: September 16, 2026	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB